



HCC- UK Annual Conference
'The MDT approach to HCC management'
Clare College, Cambridge

Thursday 21st March 2024 – Basic and Translational Science Day

11:00–12:00 Registration – arrivals, coffee and networking

Session 1 – Risk Prediction of liver disease and HCC (Chair: Dr Matthew Hoare)

12:00-12:05 Welcome and Introduction – Matt Hoare, University of Cambridge

12:05-12:30 Mendelian randomization: how can genetic variants help us triage therapeutic targets? - Stephen Burgess, Statistician, University of Cambridge

12:30-12:40 The impact of competing risk bias in prognostic models for hepatocellular carcinoma in patients with cirrhosis – Laura Burke, Leeds Teaching Hospitals Trust

12:40-13:05 Understanding risk for targeted surveillance strategies in HCC – Professor Pierre Nahon, Professor of Hepatology, APHP Avicenne Hospital

13:05-13:30 Genetic determinants of MASLD-HCC: from lipotoxicity to inflammation – Professor Luca Vittorio Carlo Valenti, Università degli Studi di Milano, Italy

13:30–14:40 Lunch and poster viewing

Session 2 – Molecular mechanisms and markers (Chair: Prof Shish Shetty, Prof Luca Valenti)

14:45 - 14:55 Unravelling bacterial metabolites using High-Resolution Magic-Angle-Spinning NMR spectroscopy in intact HCC liver tissue - Wendy Fernandes, Roger Williams Institute of Hepatology, Foundation for Liver Research.

14:55 - 15:05 The potential of BH3-mimetics as radio-sensitisation therapies in Hepatocellular carcinoma - Bashaer Alqarafi, CRUK Scotland Institute.

15:05 - 15:15 Exploring the role of TSPAN6 in regulating macrophage phenotype within the ductular reaction in the pre-cancerous niche - James Kennedy, University of Birmingham.

15:15 - 15:25 Investigation of Bap1 in hepatocarcinogenesis through the development of novel preclinical models of HCC - Anastasia Georgakopoulou, CRUK Scotland Institute.

15:25-15:35 Exploration of circulating blood cells RNA for predictive biomarker discovery in patients with hepatocellular carcinoma – Dr Ruchi Shukla, Northumbria University



15:35-16:00 Understanding the functional heterogeneity of hepatic macrophages in MASLD and MASLD-HCC – Professor Charlotte Scott, PI, VIB-UGent Center for Inflammation Research

16:00–16:40 Tea and Coffee

Session 3 – Tumour microenvironment and development (Chair: Prof Tom Bird)

16:45 – 16:55 Immunosuppressive CD73 is upregulated on tumour endothelium and may limit effective immune infiltrate in hepatocellular carcinoma - Rosemary Faulkes, University of Birmingham.

16:55 - 17:05 Engineering NK cell immunotherapy to optimise liver homing and T cell regulation - Mariana Diniz, UCL.

17:05 – 17:15 CLEC14A regulates neutrophil recruitment across liver endothelial cells and correlates with a neutrophil signature in hepatocellular carcinoma - Shish Shetty, University of Birmingham.

17:15-17:45 Interplay between senescent cells and the adaptive immune system – Dr Manuel Serrano, Principal Investigator, Altos Labs, Cambridge Institute of Science

19:15 Dinner at Sidney Sussex College (arrival 7.15pm, dinner 7.30pm)

Friday 22nd March 2024 - Clinical Day

8:00-9:00 Registration and coffee

8:20-8:50 Symposium – AstraZeneca

Challenges in HCC: performing diagnosis and patient selection when faced with co-morbidities

Professor Tom Bird - Consultant Hepatologist, University of Edinburgh

Professor Jeffry Evans, Professor, University of Glasgow

9:00-9:05 Welcome and Introduction to the Clinical Day – Dr Teik Choon See and Dr Victoria Snowdon

Session 4 - Early detection and HCC prevention (Chairs Dr Teik Choon See, Dr Victoria Snowdon)

9:05-10:25 Diagnostic difficulties in Hepatocellular carcinoma – Cases (25 mins each)

MDT panel: Dr Dave Bowden (radiology), Dr Teik Choon See (interventional radiology), Dr Owen Cain (pathology), Dr Richard Hubner (Oncology), Professor Nigel Heaton (surgery), Donna Goodge (CNS), Dr Louisa Vine (hepatologist), Dr Victoria Snowdon (hepatologist)



- Radiology perspective 'atypical imaging features' – Dr Dave Bowden, Consultant HPB/GI Radiologist, Cambridge University Hospitals
- Pathology perspective 'well differentiated hepatocellular lesions' – Dr Owen Cain, Consultant Histopathologist, Queen Elizabeth Hospital Birmingham
- Hepatology perspective 'detecting/ surveying small lesions / screening program' – Dr Louisa Vine, Consultant Hepatologist, Derriford Hospital

10:25-10:40 British Liver Trust – Liver cancer policy - Pamela Healy OBE, CEO, British Liver Trust

10:40-11:05 Improving health inequality in HCC diagnosis 'Community surveillance pilots' – Professor Graham Foster, Professor of Hepatology, QMUL, Barts Health NHS Trust

11:05-12:00 Coffee, posters and exhibition

11:25-11:55 Symposium - Roche

Managing advanced HCC: Exploring patient journeys with systemic therapy

Dr Tony Dhillon - Consultant Medical Oncologist and Senior Lecturer in Oncology at the Royal Surrey Hospital NHS Foundation Trust and Dr Sanju Mathew - Consultant Gastroenterologist and Hepatologist at the Royal Surrey Hospital NHS Foundation Trust

Session 5 - Improving HCC outcomes (Chairs: Dr Aileen Marshall, Dr Teik Choon See)

12:00-12:40 KEYNOTE Developments in the diagnosis and management of HCC – Professor John Olynyk, Associate Dean Medicine, Head of Medicine Discipline, Curtin University

12:30-12:50 HCC minimal listing criteria – Dr Abid Suddle, Hepatologist, Kings college, London

13:00-13:30 Expanding the utility of systemic therapy – neo adjuvant and adjuvant trials – Professor Tim Meyer, Experimental Cancer Medicine, UCL

13:30-14:35 Lunch, posters and exhibition

14:00-14:30 Symposium – Sirtex

HCC MDT – Interactive Cases (Chair) Dr Timothy Cross, Consultant Hepatologist, Liverpool,

Dr Teik Choon See - Consultant Interventional Radiologist, Cambridge University Hospitals NHS Foundation Trust
Professor Helen Reeves – Consultant Hepatologist – Newcastle
Professor Rohini Sharma – Consultant Medical Oncologist, Imperial College, London
Professor Nigel Heaton – Consultant Surgeon – Hepatobiliary and Pancreatic Surgery / Liver Transplantation, Kings College London

Session 6 – Decision making in the MDT (Chairs: Prof Tim Meyer, Dr Victoria Snowden)

14:35-15:15 Debate 'Resection versus RFA for smaller < 3cm tumours'

FOR: Professor Jens Ricke, Director Clinic and Polyclinic for Radiology, LMU Clinic Munich
AGAINST: Mr Paul Gibbs, Associate Professor/Transplant surgeon, Addenbrooke's Hospital, Cambridge



15:15-15:45 The evolving role of the HCC CNS - Sarah Selemeni, Lead Nurse – HCC, Kings College Hospital, London.

15:45-16:15 Intermediate stage HCC – what is best for my patient? – Dr Richard Jackson, Senior Lecturer, University of Liverpool

16:15-16:45 Advanced stage HCC – what is best for my patient? (SS versus IR versus combination) – Professor Ardnt Vogel, Physician scientist, Toronto General Hospital

16:45 - 16:50 Conclusion/Farewell/Prize giving

This educational event is supported by an unrestricted grant from the following commercial organisations:

GOLD SPONSORS



SILVER SPONSORS



EXHIBITION SPONSORS

